222 related articles for article (PubMed ID: 19814921)
21. Targeting the mast cell in asthma.
Peachell P
Curr Opin Pharmacol; 2005 Jun; 5(3):251-6. PubMed ID: 15907911
[TBL] [Abstract][Full Text] [Related]
22. Toll-like receptor modulators: a patent review (2006-2010).
Basith S; Manavalan B; Lee G; Kim SG; Choi S
Expert Opin Ther Pat; 2011 Jun; 21(6):927-44. PubMed ID: 21406035
[TBL] [Abstract][Full Text] [Related]
23. Monoclonal antibodies and other biologic agents in the treatment of asthma.
Long AA
MAbs; 2009; 1(3):237-46. PubMed ID: 20065638
[TBL] [Abstract][Full Text] [Related]
24. 7. Control of allergic airway inflammation through immunomodulation.
Corry DB; Kheradmand F
J Allergy Clin Immunol; 2006 Feb; 117(2 Suppl Mini-Primer):S461-4. PubMed ID: 16455347
[TBL] [Abstract][Full Text] [Related]
25. Anti-immunoglobulin E therapy with omalizumab for asthma.
Hendeles L; Sorkness CA
Ann Pharmacother; 2007 Sep; 41(9):1397-410. PubMed ID: 17698897
[TBL] [Abstract][Full Text] [Related]
26. Spotlight on omalizumab in allergic asthma.
Bang LM; Plosker GL
BioDrugs; 2004; 18(6):415-8. PubMed ID: 15571425
[TBL] [Abstract][Full Text] [Related]
27. Advanced Molecular Knowledge of Therapeutic Drugs and Natural Products Focusing on Inflammatory Cytokines in Asthma.
Lin SC; Shi LS; Ye YL
Cells; 2019 Jul; 8(7):. PubMed ID: 31284537
[TBL] [Abstract][Full Text] [Related]
28. Toll-like receptor 9 activation with CpG oligodeoxynucleotides for asthma therapy.
Kline JN; Krieg AM
Drug News Perspect; 2008 Oct; 21(8):434-9. PubMed ID: 19034349
[TBL] [Abstract][Full Text] [Related]
29. Novel treatments of asthma and allergic diseases.
Chini L; Monteferrario E; Graziani S; Moschese V
Paediatr Respir Rev; 2014 Dec; 15(4):355-62. PubMed ID: 24287269
[TBL] [Abstract][Full Text] [Related]
30. Biologic therapies for asthma.
Gruenberg D; Busse W
Curr Opin Pulm Med; 2010 Jan; 16(1):19-24. PubMed ID: 19797955
[TBL] [Abstract][Full Text] [Related]
31. Intranasal administration of CpG oligodeoxynucleotides reduces lower airway inflammation in a murine model of combined allergic rhinitis and asthma syndrome.
Li HT; Zhang TT; Chen ZG; Ye J; Liu H; Zou XL; Wang YH; Yang HL
Int Immunopharmacol; 2015 Sep; 28(1):390-8. PubMed ID: 26163938
[TBL] [Abstract][Full Text] [Related]
32. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).
Milgrom H; Berger W; Nayak A; Gupta N; Pollard S; McAlary M; Taylor AF; Rohane P
Pediatrics; 2001 Aug; 108(2):E36. PubMed ID: 11483846
[TBL] [Abstract][Full Text] [Related]
33. New Targeted Therapies for Uncontrolled Asthma.
Corren J
J Allergy Clin Immunol Pract; 2019; 7(5):1394-1403. PubMed ID: 31076057
[TBL] [Abstract][Full Text] [Related]
34. The effect of omalizumab treatment on the low affinity immunoglobulin E receptor (CD23/fc epsilon RII) in patients with severe allergic asthma.
Assayag M; Moshel S; Kohan M; Berkman N
Allergy Asthma Proc; 2018 Jan; 39(1):36-42. PubMed ID: 29279058
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic potential of Toll-like receptor 9 activation.
Krieg AM
Nat Rev Drug Discov; 2006 Jun; 5(6):471-84. PubMed ID: 16763660
[TBL] [Abstract][Full Text] [Related]
36. Omalizumab: a review of its use in the management of allergic asthma.
Bang LM; Plosker GL
Treat Respir Med; 2004; 3(3):183-99. PubMed ID: 15219177
[TBL] [Abstract][Full Text] [Related]
37. Toll-like receptors as targets for allergen immunotherapy.
Aryan Z; Rezaei N
Curr Opin Allergy Clin Immunol; 2015 Dec; 15(6):568-74. PubMed ID: 26418475
[TBL] [Abstract][Full Text] [Related]
38. Omalizumab: a review of its use in the treatment of allergic asthma.
Plosker GL; Keam SJ
BioDrugs; 2008; 22(3):189-204. PubMed ID: 18481901
[TBL] [Abstract][Full Text] [Related]
39. Immune response modifiers in the treatment of asthma: A PRACTALL document of the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergy and Clinical Immunology.
Ballow M; Akdis CA; Casale TB; Wardlaw AJ; Wenzel SE; Ballas Z; Lötvall J
J Allergy Clin Immunol; 2012 Aug; 130(2):311-24. PubMed ID: 22713596
[No Abstract] [Full Text] [Related]
40. Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection.
Cruz AA; Lima F; Sarinho E; Ayre G; Martin C; Fox H; Cooper PJ
Clin Exp Allergy; 2007 Feb; 37(2):197-207. PubMed ID: 17250692
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
